Given the poor efficacy of traditional adjuvant CT and the advent of KRAS-targeted therapies, there is a growing interest in exploring combination approaches with KRASi in early settings to enhance the therapeutic efficacy and overcome resistance mechanisms, thereby improving clinical outcomes for NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.